# Nilotinib for First-line Newly Diagnosed CML-CP Patients

> **NCT03942094** · PHASE3 · UNKNOWN · sponsor: **Shenzhen Second People's Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia, Chronic Phase
- Nilotinib

## Interventions

- **DRUG:** Nilotinib

## Key facts

- **NCT ID:** NCT03942094
- **Lead sponsor:** Shenzhen Second People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-01
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-03-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03942094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03942094, "Nilotinib for First-line Newly Diagnosed CML-CP Patients". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT03942094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*